SCHEMBL31436451

SCHEMBL31436451

COc1nn(C2CC(C)(O)C2)c2c(C(F)(F)F)cc(O)cc12

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.37
IL1B P01584 3/20 0.32
LRRK2 Q5S007 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31436460 0.88 AR (0.34) ARLRRK2
SCHEMBL31349577 0.85 AR (0.39) ARIL1B
SCHEMBL31436493 0.82 AR (0.31) AR
SCHEMBL31436537 0.81 AR (0.31) AR
SCHEMBL31436484 0.81 AR (0.46) ARIL1B
SCHEMBL25313086 0.74 AR (0.40) ARIL1BLRRK2
SCHEMBL30507063 0.74 AR (0.40) ARIL1BLRRK2
SCHEMBL30507049 0.74 AR (0.40) ARIL1B
SCHEMBL25316359 0.74 AR (0.40) ARIL1B
SCHEMBL25924822 0.74 AR (0.40) ARIL1BLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743079-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015106-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed